Results 131 to 140 of about 3,203 (180)
Some of the next articles are maybe not open access.
THE ROLE OF PARICALCITOL ON PROTEINURIA
Journal of Renal Care, 2011SUMMARYParicalcitol is a synthetic vitamin D analogue acting on vitamin D receptor (VDR). The result is inhibition of PTH synthesis and secretion. Paricalcitol appears also to block the renin–angiotensin–aldosterone system. We evaluated the role of paricalcitol in the management of proteinuria of various aetiology.
Georgios Aperis, Christos Paliouras
exaly +3 more sources
The Impact of Paricalcitol on Left Ventricular Hypertrophy
, 2011 Cardiovascular (CV) morbidity and mortality are significantly higher in patients with chronic kidney disease (CKD). Mineral metabolism disorders, such as hyperphosphatemia, hypocalcemia, and vitamin D deficiency, have been deeply associated not only with bone disease, but also with vascular calcification and CV disease.
Cozzolino M, Ronco C
openaire +5 more sources
Antiproteinuric effect of oral paricalcitol in chronic kidney disease
Kidney International, 2005 Antiproteinuric effect of oral paricalcitol in chronic kidney disease.BackgroundProteinuria is a marker of cardiovascular and renal disease in patients with chronic kidney disease (CKD), and reduction in proteinuria has been associated with improved ...
Rajiv Agarwal +2 more
exaly +2 more sources
Paricalcitol Improves Hypoxia-Induced and TGF-β1-Induced Injury in Kidney Pericytes
International Journal of Molecular Sciences, 2021 Recently, the role of kidney pericytes in kidney fibrosis has been investigated. This study aims to evaluate the effect of paricalcitol on hypoxia-induced and TGF-β1-induced injury in kidney pericytes.
Jeong-Hoon Lim +2 more
exaly +2 more sources
Treatments in Endocrinology, 2006
black triangle An oral formulation of paricalcitol has been developed for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease.black triangle Paricalcitol is a synthetic vitamin D analog that binds to the vitamin D receptor inducing suppression of parathyroid hormone (PTH) secretion.black ...
Emma D, Deeks +1 more
+7 more sources
black triangle An oral formulation of paricalcitol has been developed for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease.black triangle Paricalcitol is a synthetic vitamin D analog that binds to the vitamin D receptor inducing suppression of parathyroid hormone (PTH) secretion.black ...
Emma D, Deeks +1 more
+7 more sources
Paricalcitol attenuates cyclosporine-induced kidney injury in rats
Kidney International, 2010 Despite its benefits, the clinical use of cyclosporine A (CsA) is limited by its nephrotoxic properties. Because paricalcitol (19-nor-1,25-hydroxyvitamin D2) has renoprotective effects, we tested whether it can blunt renal dysfunction and fibrosis in a ...
Eun Hui Bae, In Jin Kim, Seong Kwon
exaly +2 more sources
Kidney International, 2008 Vitamin D derivatives and calcimimetics are used to treat secondary hyperparathyroidism in patients with chronic renal failure. We investigated the effect of calcitriol, paricalcitol, and the calcimimetic AMG 641 on soft-tissue calcification in uremic ...
FRANCISCO J Mendoza +2 more
exaly +2 more sources
Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease [PDF]
Pediatric Nephrology, 2017 BACKGROUND: Elevated intact parathyroid hormone (iPTH) levels can contribute to morbidity and mortality in children with chronic kidney disease (CKD). We evaluated the pharmacokinetics, efficacy, and safety of oral paricalcitol in reducing iPTH levels in
Nicholas J A Webb +2 more
exaly +2 more sources